Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine discovery, development and delivery, announced today that Dr. J. Joseph Kim, CEO, will present at Needham & Company’s 8th Annual Life Sciences Conference on Thursday, June 11, 2009, at 3:00 p.m. ET. The conference will be held at the New York Palace Hotel.

Inovio completed a merger with VGX Pharmaceuticals on June 1, 2009. This will be the combined company’s first presentation of its DNA vaccine development plans.

A live webcast of the presentation will be available by going to www.inovio.com. An archived replay will be available for a period of 30 days.

About Inovio Biomedical Corporation

Inovio Biomedical is engaged in the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The company’s SynCon™ technology enables the design of DNA-based vaccines better-targeted to desired immune system mechanisms and capable of providing cross-protection against evolving, unmatched strains of pathogens such as influenza. Inovio’s proprietary electroporation DNA delivery technology uses brief, controlled electrical pulses to increase cellular DNA vaccine uptake. Initial human data has shown this method can safely and significantly increase gene expression and immune responses. Inovio’s clinical programs include HPV/cervical cancer (therapeutic) and HIV vaccines. An IND has been filed for an avian influenza vaccine. Partners and collaborators include Merck, Tripep, University of Southampton, University of Pennsylvania, and HIV Vaccines Trial Network. Inovio’s product candidates and technologies are protected by an extensive global intellectual property portfolio. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines.